Monday Afternoon Analyst Upgrades and Downgrades: Caesars, Coinbase, Editas, Wynn and More24/7 Wall Street • 08/09/21
Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More24/7 Wall Street • 08/05/21
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell MedicinesGlobeNewsWire • 07/29/21
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021The Motley Fool • 07/23/21
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This WeekThe Motley Fool • 07/16/21
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are ExplodingThe Motley Fool • 07/15/21
Do Options Traders Know Something About Editas Medicine (EDIT) Stock We Don't?Zacks Investment Research • 07/07/21